Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of STSA-1201 in Healthy Subjects
NCT05986877Phase 1Completed
- Sponsor
- Staidson Biopharmaceutical
- Start
- Aug 2023
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of STSA-1201 in asthma (4 arms), sponsored by Staidson Biopharmaceutical. Primary endpoint: Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram, Vital Signs And Physical Examination Abnormalities. Started Aug 2023; status: completed.
02
Drugs
STSA-1201
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05986877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05986877.